SYSTEMATIC REVIEW

Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: A living systematic review [version 1; peer review: awaiting peer review]

Michel Jacques Counotte 1, Kaspar Walter Meili 1, Katayoun Taghavi 1, Guilherme Calvet 2, James Sejvar 3, Nicola Low 1

1 Institute of Social and Preventive Medicine, University Bern, Bern, Switzerland
2 Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil
3 Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Abstract

Background: The Zika virus (ZIKV) caused a large outbreak in the Americas leading to the declaration of a Public Health Emergency of International Concern in February 2016. A causal relation between infection and adverse congenital outcomes such as microcephaly was declared by the World Health Organization (WHO) informed by a systematic review structured according to a framework of ten dimensions of causality, based on the work of Bradford Hill. Subsequently, the evidence has continued to accumulate, which we incorporate in regular updates of the original work, rendering it a living systematic review.

Methods: We present an update of our living systematic review on the causal relation between ZIKV infection and adverse congenital outcomes and between ZIKV and GBS for four dimensions of causality: strength of association, dose-response, specificity, and consistency. We assess the evidence published between January 18, 2017 and July 1, 2019.

Results: We found that the strength of association between ZIKV infection and adverse outcomes from case-control studies differs according to whether exposure to ZIKV is assessed in the mother (OR 3.8, 95% CI: 1.7-8.7, I²=19.8%) or the foetus/infant (OR 37.4, 95% CI: 11.0-127.1, I² =0%). In cohort studies, the risk of congenital abnormalities was 3.5 times higher after ZIKV infection (95% CI: 0.9-13.5, I²=0%). The strength of association between ZIKV infection and GBS was higher in studies that enrolled controls from hospital (OR: 55.8, 95% CI: 17.2-181.7, I²=0%) than in studies that enrolled controls at random from the same community or household (OR: 2.0, 95% CI: 0.8-5.4, I²=74.6%). In case-control studies, selection of controls from hospitals could have biased results.

Conclusions: The conclusions that ZIKV infection causes adverse congenital outcomes and GBS are reinforced with the evidence published between January 18, 2017 and July 1, 2019.
Keywords
Zika, Disease outbreaks, arboviruses, causality, Guillain-Barré syndrome, congenital abnormalities

This article is included in the Living Evidence collection.

This article is included in the Zika & Arbovirus Outbreaks collection.

Corresponding authors: Michel Jacques Counotte (michel.counotte@ispm.unibe.ch), Nicola Low (nicola.low@ispm.unibe.ch)

Author roles: Counotte MJ: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Visualization, Writing – Original Draft Preparation; Meili KW: Data Curation, Investigation, Methodology, Validation, Writing – Review & Editing; Taghavi K: Data Curation, Validation, Writing – Review & Editing; Calvet G: Validation, Writing – Review & Editing; Sejvar J: Validation, Writing – Review & Editing; Low N: Conceptualization, Data Curation, Funding Acquisition, Supervision, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Swiss National Science Foundation [320030_170069], end date: 31/10/2021
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Counotte MJ et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Counotte MJ, Meili KW, Taghavi K et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: A living systematic review [version 1; peer review: awaiting peer review] F1000Research 2019, 8:1433 (https://doi.org/10.12688/f1000research.19918.1)

First published: 14 Aug 2019, 8:1433 (https://doi.org/10.12688/f1000research.19918.1)
Introduction

The Zika virus (ZIKV), a mosquito-borne flavivirus, caused a large outbreak of infection in humans in the Americas between 2015–2017 (WHO Zika -Epidemiological Update). Since then, the circulation of ZIKV has decreased substantially in the Americas but ZIKV transmission will likely continue at a lower level. Smaller outbreaks have been reported from countries in Africa and Asia, including Angola, India, and Singapore. Regions with endemic circulation, such as Thailand, have the potential for new ZIKV outbreaks with adverse outcomes.

The World Health Organization (WHO) declared ZIKV as a cause of adverse congenital outcomes and Guillain-Barré syndrome (GBS) as early as September 2016, informed by a systematic review of evidence structured according to a framework of ten dimensions of causality, based on Bradford Hill (Table 1). The accumulation of evidence on the adverse clinical outcomes of ZIKV has barely slowed down since the WHO declared the Public Health Emergency of International Concern (PHEIC) on February 1st, 2016, with approximately 250 research publications on ZIKV appearing every month (see Zika Open Access Project). We updated the systematic review to January 18, 2017 as a living systematic review by introducing automated search methods to produce a high quality, up to date, online summary of research about ZIKV and its clinical consequences, for all the causality dimensions.

Since 2017, understanding about the pathogenesis of how ZIKV causes congenital abnormalities has evolved. The quality of diagnostic methods, especially for acute ZIKV infection, has also improved. More importantly, understanding of the limitations of diagnostic testing, and the need for interpretation in the context of other flavivirus infections, has developed. Important epidemiological questions about the associations between ZIKV infection and adverse congenital outcomes and GBS remain unanswered, however. Much of the early epidemiological evidence, which relied on surveillance data, was limited in use because of issues with the quality of the reporting and case definitions. The reported strength of association between ZIKV and adverse outcomes has varied in studies of different designs and in different settings. Evidence for a dose-response relationship with higher levels of exposure to ZIKV resulting in more severe outcomes, of clinical findings that are specific to ZIKV infection, or of adverse outcomes caused by different lineages of ZIKV was not found in the earlier systematic reviews.

The objective of this study is to update epidemiological evidence about associations between ZIKV infection and adverse congenital outcomes and between ZIKV and GBS for four dimensions of causality: strength of association, dose-response, specificity, and consistency.

Methods

We performed a living systematic review, which we have described previously. This review updates the findings of the previous reviews and will be kept up to date, in accordance with the methods described below. Reporting of the results follows

Table 1. Comparison of the search strategy included study designs and causality dimensions addressed in the different review periods. The latest and previous versions of this table are available as extended data.

<table>
<thead>
<tr>
<th>Review</th>
<th>Baseline*</th>
<th>Update 1</th>
<th>Update 2 [this review]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Search strategy</td>
<td>“ZIKV” or “Zika”</td>
<td>“ZIKV” or “Zika”</td>
<td>Focussed search strategy (Supplementary File 2)</td>
</tr>
<tr>
<td>Study design</td>
<td>Epidemiological studies; in vivo/in vitro studies; surveillance reports</td>
<td>Epidemiological studies</td>
<td></td>
</tr>
<tr>
<td>Dimensions of the causality framework based on Bradford Hill*</td>
<td>• Temporality (cause precedes effect)</td>
<td>• Strength of association</td>
<td>• Strength of association</td>
</tr>
<tr>
<td></td>
<td>• Biological plausibility of proposed biological mechanisms</td>
<td>• Exclusion of alternative explanations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Strength of association</td>
<td>• Cessation (reversal of an effect by experimental removal of, or observed a decline in, the exposure)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Exclusion of alternative explanations</td>
<td>• Dose-response relationship</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Cessation (reversal of an effect by experimental removal of, or observed a decline in, the exposure)</td>
<td>• Experimental evidence from animal studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dose-response relationship</td>
<td>• Analogous cause-and-effect relationships found in other diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Exclusion of alternative explanations</td>
<td>• Specificity of the effect</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Specificity of the effect</td>
<td>• Consistency of findings across different study types, populations and times</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consistency of findings across different study types, populations and times</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The causality framework is described elsewhere in detail: [https://f1000researchdata.s3.amazonaws.com/supplementary/13704/95380c74-7569-4049-bf3b-b2832794bdf9.docx].
the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement (Extended data, Supplementary File 1)\(^1\).

**Focus on epidemiological aspects of causality**

This review and subsequent updates will focus on four dimensions of causality that are examined in epidemiological study designs: strength of association, dose-response relationship and specificity of effects and consistency of association (Extended data, Table 1, Supplementary File 2\(^1\)). Evidence for domains of causality that are typically investigated in *in vitro* and *in vivo* laboratory studies (Table 1) was not sought. In the absence of licensed vaccines or treatments for ZIKV infection, we did not search for evidence on the effects of experimental removal of ZIKV.

**Eligibility criteria**

We considered epidemiological studies that reported original data and assessed ZIKV as the exposure and congenital abnormalities or GBS as the outcomes. We based the exposure and outcome assessment on the definitions used in the publications. We applied the following specific inclusion criteria (Extended data, Supplementary File 2\(^1\)):

- **Strength of association:** at the individual level, we selected studies that included participants both with and without exposure to ZIKV (Figure 1), such as cohort studies and case-control studies. At the population level, we included studies that assessed the outcome during the ZIKV outbreak and provided a comparison with pre or post-outbreak incidence of the outcome.

- **Dose-response relationship:** we included studies that assessed the relation between the level of the viral titre or the presence or severity of the symptoms and the occurrence or severity of the outcome.

- **Specificity of the outcome for ZIKV exposure:** we included studies that assessed whether the pathological findings in cases with the outcome are specific for ZIKV infection.

- **Consistency:** we looked at eligible studies to determine the consistency of the relationship between ZIKV exposure and the outcomes across populations, study designs, regions or strains.

**Search and information sources**

We searched PubMed, Embase, LILACS and databases and websites of defined health agencies (Extended data, Supplementary File 2\(^1\)). We included search terms for the exposure, the outcome and specific study designs. We also performed searches of the reference lists of included publications. A detailed search strategy is presented in Supplementary File 2. For this review, the search covered the period from January 19, 2017 to July 1, 2019.

**Study selection and extraction**

One reviewer screened titles and abstracts of retrieved publications. If retained, the same reviewer screened the full text for inclusion. A second reviewer verified decisions. One reviewer extracted data from included publications into piloted extraction forms in REDCap (version 8.1.8 LTS, Research Electronic Data Capture)\(^1\). A second reviewer verified data entry. Conflicts were resolved by consulting a third reviewer.

**Synthesis of evidence**

First, we summarised findings for each dimension of causality and for each outcome descriptively. Where available, we calculated unadjusted odds ratios (OR) or risk ratios (RR) and their 95% confidence interval (CI) from published data for unmatched study designs. For matched study designs, we used the effect measure and 95% CI presented by the authors. For publications that presented results for multiple measures of exposure and/or outcome, we compared these results. We applied the standard continuity correction of 0.5 for zero values in any cell in the two-by-two table\(^2\). We used the I\(^2\) statistic to describe the percentage of variation across studies that is due to heterogeneity for reasons other than chance\(^3\). Quantitative synthesis was performed using R 3.5.1\(^4\). We conducted random effects meta-analyses using the R package metafor (version 2.0-0)\(^5\). Finally, we compared descriptive and quantitative

---

**Figure 1.** For congenital abnormalities due to ZIKV, exposure assessment in mother-infant pairs can be performed in the mother or the foetus or infant. The latest and previous versions of this figure are available as extended data\(^1\).
findings from this review period with previous versions of the review.\textsuperscript{8,10}\textsuperscript{8}

**Searching and screening frequency**

Daily searches of PubMed, Embase and LILACS are automated and monthly searches are performed manually for other information sources in the first week of the month (Extended data, Supplementary File 2\textsuperscript{7}). With screening of all retrieved publications on the same day. The search strategy consisted of a combination of free terms and MESH terms that identified the exposure and outcomes (Extended data, Supplementary File 2\textsuperscript{7}). Searches from multiple sources were combined and automatically deduplicated by an algorithm that was tested against manual deduplication. Unique records enter a central database, and reviewers are notified of new content.

**Frequency of results update**

The tables and figures presented in this paper will be updated every six months as a new version of this publication. As soon as new studies are included, their basic study characteristics are extracted and provided online [https://zika.ispm.unibe.ch/assets/data/pub/causalityMap/](https://zika.ispm.unibe.ch/assets/data/pub/causalityMap/).

**Duration of maintenance of the living systematic review**

We will keep the living systematic review up to date for as long as new relevant data are published and at least until October 31, 2021, the end date of the project funding.

**Risk of bias/Certainty of evidence assessment**

To assess the risk of bias of cohort studies and case-control studies, we compiled a list of questions in the domains of selection bias, information bias, and confounding, based on the quality appraisal checklist of the United Kingdom National Institute for Health and Care Excellence (NICE) and literature.\textsuperscript{11}

Two independent reviewers conducted the quality assessment. Disagreements were resolved by a third reviewer.

**Results**

**Search results from January 19, 2017 to July 1, 2019 (Update 2)**

From January 19, 2017 to July 1, 2019 we screened 1941 publications, of which we included 638 based on title and abstract. After reviewing the full text, 249 publications were included (Table 2, Figure 3). Of these publications, 195 reported on congenital abnormalities linked to ZIKV\textsuperscript{124–217} and 59 on GBS.\textsuperscript{44,118,201,203,206,218–270} Five outbreak reports described both outcomes.\textsuperscript{14,118,201,203,206}

**Adverse congenital outcomes**

We included 39 case reports\textsuperscript{24–61}, 62 case series\textsuperscript{62–123}, 10 case-control studies\textsuperscript{24–133}, 35 cohort studies\textsuperscript{134–168}, 19 cross-sectional studies\textsuperscript{169–187}, seven ecological studies\textsuperscript{188–194}, three modelling studies\textsuperscript{195–197} and 20 outbreak reports\textsuperscript{198–217} that report on congenital abnormalities linked to ZIKV.

**Causality dimensions**

**Strength of association. Individual level:** In this review period, five case-control studies reported on strength of association, four in Brazil (n=670 participants)\textsuperscript{25,125,128,130} and one in French Polynesia (n=123 participants)\textsuperscript{131}. The studies assess adverse pregnancy outcomes including infants born with microcephaly, according to exposure to ZIKV for cases. Of these, all studies matched controls, based on gestational age and/or region. During the review period up to January 18, 2017, we included one case-control study\textsuperscript{201}, which we replaced with a publication reporting the final results of the study.\textsuperscript{126} The meta-analyses incorporate estimates from studies identified in all review periods.

**Table 2. Included publications in the baseline review, update 1 and update 2 (this version), by outcome and epidemiological study design.** The latest and previous versions of this table are available as extended data.\textsuperscript{16}

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Adverse congenital outcomes, number of publications</th>
<th>GBS, number of publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline*</td>
<td>Update 1\textsuperscript{†}</td>
<td>Update 2</td>
</tr>
<tr>
<td>Case report</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>Case series</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td>Case-control study</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Cohort study</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Cross-sectional study</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Controlled trials</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ecological study/outbreak report</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Modelling study</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Total:</td>
<td>41</td>
<td>40</td>
</tr>
</tbody>
</table>

\* Baseline review, earliest date of each information source to May 30, 2016.\textsuperscript{16}

\textsuperscript{†} Update 1, May 30, 2016 to January 18, 2017.\textsuperscript{16}
Assessment of exposure status varied between the studies (Extended data, Supplementary File 3). In five case-control studies, exposure to ZIKV was assessed in the mother, based on clinical symptoms of ‘suspected Zika virus infection’, or presence of maternal antibodies measured by IgM (Kumar et al. (2016)), PRNT (de Araujo et al. (2018), Subissi et al. (2018)), or both PRNT and IgG (Moreira-Soto et al. (2018)) maternal antibody.

In meta-analysis, we found that the odds of adverse congenital outcomes (microcephaly or congenital abnormalities) were 3.8 times higher in ZIKV-infected mothers (95% CI: 1.7-8.7, tau²=0.18, I²=19.8%, Figure 4). Moreira-Soto et al. (2018) found that in Bahia, Brazil, Chikungunya infection was also associated with being a case.

In two matched case-control studies, exposure to ZIKV was assessed in infants; Araujo et al. found a 73.1 (95% CI 13.0–Inf) times higher odds was reported for microcephaly when ZIKV infection was assessed by reverse transcription polymerase chain reaction (RT-PCR) in the neonate. Krow-Lucal et al. (2018) found an OR of 21.9 (95% CI: 7.0-109.3) based on evidence of recent Zika infection assessed using IgM followed by PRNT in infants in Paraiba, Brazil. When exposure was assessed at the infant-level, the combined odds of adverse congenital outcomes was 37.4 times higher (95% CI: 11.0-127.1, tau²=0, I²=0%, Figure 4).

In this review period, one cohort study reported on strength of association, in 610 pregnant women returning from ZIKV-affected areas in Central and South America to the USA. Maternal ZIKV exposure was measured using RT-PCR or IgM followed by plaque reduction neutralisation test (PRNT). Among the 28 infants born to ZIKV-infected mothers, none was diagnosed with microcephaly and, one was born with a major malformation. In the ZIKV-unexposed group, eight out of 306 had major malformations. A complete overview of different outcomes assessed is presented in the extended data, Supplementary File 3. During the review period up to January 18, 2017, we included two cohort studies, one in women with rash and fever (Brasil et al. (2016)) and one in unselected pregnant women (Pomar et al. (2017)). In meta-analysis of all three studies, we found that the risk of microcephaly was 3.5 times higher in ZIKV-infected mothers of babies (95% CI: 0.90-13.51, tau²=0, I²=0%, Figure 5).

**Population level:** At a population level, data from Mexico collected at different altitudes during the ZIKV outbreak, showed...
that the risk of microcephaly was increased in regions at altitudes below 2200m, in which ZIKV can circulate\textsuperscript{196}. Hay et al. (2018) reanalysed surveillance data from Colombia and northeast Brazil and concluded that time-dependent reporting changes might have caused apparent inconsistencies in the proportion of congenital abnormalities as a result of maternal ZIKV infection\textsuperscript{197}.

**Dose response.** Halai et al. (2017)\textsuperscript{120} examined the severity of congenital outcomes according to measures of the severity of maternal ZIKV infection in a subset of mothers in the cohort presented by Brasil et al. (2016)\textsuperscript{274}. They evaluated ZIKV load, assessed by RT-PCR using the cycle threshold (CT) as a measure of number of RNA copies, and a severity score of symptoms in 131 pregnant women. They concluded that neither higher viral load nor more severe symptoms was associated with more severe congenital abnormalities\textsuperscript{136}. Moreira-Soto et al. found higher maternal antibody titers in microcephaly cases compared with controls\textsuperscript{127}. In previous review periods, Honein et al. (2016) compared outcomes in neonates born to symptomatic and asymptomatic infected pregnant women returning to the USA with possible ZIKV infection and found no differences\textsuperscript{275}.

**Specificity.** Although some outcomes, such as lingual phenotype\textsuperscript{177} or neurogenic bladder\textsuperscript{276}, have been hypothesised as a specific phenotype for congenital ZIKV infection, no additional evidence was identified that certain congenital adverse findings are specific for congenital ZIKV infection.

**Consistency. Geographical region:** All four WHO geographic regions (the Africa region [AFRO], the American region [AMRO], the South-East Asian region [SEARO] and the Western
**Figure 4.** Forest plot and meta-analysis of case-control studies reporting on ZIKV infection assessed in mothers (A) and in infants (B) and adverse congenital outcomes (microcephaly, congenital malformations, central nervous system abnormalities). The odds ratio from the five case-control studies that assess exposure in mothers combined is 3.8 (95% CI: 1.7-8.7, tau$^2=2.37$, I$^2=19.8\%$); the odds ratio for the studies that assess exposure in infants is 37.4 (95% CI: 11.0-127.1, tau$^2=0$, I$^2=0\%$). The odds ratios are plotted on the log scale. Abbreviations: CSF, cerebrospinal fluid, PRNT, plaque reduction neutralisation test; RE, random effects; RT-PCR, reverse transcription polymerase chain reaction. The latest and previous versions of this figure are available as extended data$^{16}$.

<table>
<thead>
<tr>
<th>Author(s), Year [exposure assessment]</th>
<th>Odds Ratio [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Matched OR, adjusted</strong></td>
<td></td>
</tr>
<tr>
<td>Moreira-Soto, 2018 [Mother: IgG + PRNT50]</td>
<td>4.00 [0.82, 19.44]</td>
</tr>
<tr>
<td>Subisai, 2018 [Mother: PRNT]</td>
<td>7.07 [0.93, 53.98]</td>
</tr>
<tr>
<td>Santa Rita, 2017 [Mother: suspected Zika virus]</td>
<td>9.88 [1.60, 60.58]</td>
</tr>
<tr>
<td>RE Model for Subgroup (Q = 0.06, df = 1, p = 0.81; $i^2 = 0%$)</td>
<td>8.50 [2.19, 32.94]</td>
</tr>
<tr>
<td><strong>Crude OR, unadjusted</strong></td>
<td></td>
</tr>
<tr>
<td>de Araujo, 2018 [Mother: PRNT50]</td>
<td>1.72 [0.61, 4.82]</td>
</tr>
<tr>
<td>Kumar, 2016 [Mother: IgM]</td>
<td>6.80 [0.51, 91.29]</td>
</tr>
<tr>
<td>RE Model for Subgroup (Q = 0.93, df = 1, p = 0.33; $i^2 = 0%$)</td>
<td>2.07 [0.79, 5.40]</td>
</tr>
<tr>
<td>RE Model for All Studies (Q = 3.81, df = 4, p = 0.43; $i^2 = 19.7%$)</td>
<td>3.82 [1.68, 8.70]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Author(s), Year [exposure assessment]</th>
<th>Odds Ratio [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>de Araujo, 2018 [Fetal: RT-PCR (serum, CSF, tissue)]</td>
<td>73.10 [11.61, 460.15]</td>
</tr>
<tr>
<td>Krow-Lucal, 2018 [Infant: IgM + PRNT (recent Zika)]</td>
<td>21.90 [4.24, 113.02]</td>
</tr>
<tr>
<td>RE Model for All Studies (Q = 0.92, df = 1, p = 0.34; $i^2 = 0%$)</td>
<td>37.36 [10.98, 127.13]</td>
</tr>
</tbody>
</table>

**Figure 5.** Forest plot and meta-analysis of cohort studies reporting on ZIKV infection and adverse congenital outcomes. The risk ratio from the random effects model is 3.5 (95% CI: 0.9-13.5, tau$^2=0$, I$^2=0\%$). The risk ratios are provided on the log scale. Abbreviations: ZIKV, Zika virus; PRNT, plaque reduction neutralisation test; RE, random effects; RT-PCR, reverse transcription polymerase chain reaction. The latest and previous versions of this figure are available as extended data.

<table>
<thead>
<tr>
<th>Author (Year) [outcome]</th>
<th>Risk ratio [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pomar (2017) [RT-PCR or IgM/ IgG]</td>
<td>4.86 [0.80, 29.36]</td>
</tr>
<tr>
<td>Brasil (2016) [RT-PCR confirmed]</td>
<td>4.42 [0.24, 80.78]</td>
</tr>
<tr>
<td>Adhikari (2017) [IgM and or PRNT]</td>
<td>1.18 [0.06, 21.31]</td>
</tr>
<tr>
<td>RE Model for All Studies (Q = 0.70, df = 2, p = 0.71; $i^2 = 0%$)</td>
<td>3.49 [0.90, 13.51]</td>
</tr>
</tbody>
</table>
Pacific region [WPRO]) with past or active ZIKV transmission have now reported congenital abnormalities due to ZIKV infection. During this review period, the first congenital abnormality due to infection with the Asian lineage of the virus on the African mainland occurred in a traveller returning from Angola. Possible cases of congenital abnormalities have occurred in Guinea-Bissau. In the most recent WHO situation report from March 2017, two cases of microcephaly are documented in Thailand and one in Vietnam, which were also described in detail in other works. We identified another publication on congenital abnormalities due to endemic ZIKV in Cambodia. The occurrence of congenital adverse outcomes in AFRO, SEARO, and WPRO seems sporadic, despite the endemic circulation of ZIKV. As noted above, the observed complication rate varied strongly between regions. Extended data, Supplementary File 3 provides a full overview of the published studies on congenital abnormalities per region and country.

Traveller/non-traveller populations: In this update, we found further evidence that congenital abnormalities occurred in infants born to women travellers returning from ZIKV-affected areas and women remaining in those areas. In total, 25 publications report on 272 congenital abnormalities due to ZIKV infection in travellers, with 109 publications reporting congenital abnormalities due to ZIKV in 2652 non-travellers.

In this review period, evidence emerged that transmission through sexual contact with infected travellers also resulted in foetal infection.

Study designs: The association between ZIKV infection and congenital abnormalities was consistent across different study designs (Table 2).

Lineages: We found no new evidence of consistency across different lineages from observational studies. The currently observed adverse congenital outcomes are linked to the ZIKV of the Asian lineage.

Risk of bias assessment
In all case-control studies, uncertainty about the exposure status due to imperfect tests could result in a bias towards the null. Some studies might suffer from recall bias where exposure was assessed by retrospectively asking about symptoms. The enrolment criteria were based on symptomatology. As a result, even in the absence of evidence of ZIKV, the unexposed groups might have had conditions that were unfavourable to their pregnancy. We expect this to bias the results towards the null or underestimate the true effect. Owing to imperfect diagnostic techniques, both false positives (IgM, cross reactivity) and false negatives (due to the limited detection window for RT-PCR) might occur, potentially resulting in bias; the direction of this bias would often be towards the null. None of the studies controlled for potential confounding. Extended data, Supplementary File 4 provides the full risk of bias assessment of the studies included in the meta-analysis.

GBS During this review period, we included 17 case reports, 22 case series, seven case-control studies, one ecological study, one modelling study and eight outbreak reports that reported on ZIKV infection and GBS.

Causality dimensions
Strength of association. Individual level. The number of studies reporting on the strength of association between ZIKV infection and GBS at an individual level increased substantially. We identified five case-control studies published since the previous update, which included one case-control study from French Polynesia. All studies were matched for age and place of residence. In the studies from Brazil, Colombia, Puerto Rico and New Caledonia, temporal clustering of cases in association with ZIKV circulation was documented. In Bangladesh, ZIKV transmission was endemic. Exposure assessment was based on serology or a combination of RT-PCR and serology. Extended data, Supplementary File 3 shows the variability in ORs according to criteria for ZIKV exposure assessment, based on unmatched crude data extracted from each case-control study.

Figure 6 shows the association between GBS and ZIKV infection, using the diagnostic criteria that were most similar across studies. Heterogeneity was considerable (I² = 78.3%), but was reduced slightly after stratification based on the method of selection of controls. The summary OR was higher in studies that enrolled controls from hospital (OR: 55.8, 95% CI: 17.2-181.7, tau²=0, I²(%)=258,277) than in studies that enrolled controls at random from within the same community or from the same household (OR: 2.0, 95% CI: 0.8-5.4, tau²=0.46, I²(%)=74.6%). Amongst studies with community controls, ORs were lower when enrolment and assessment took place several months after onset of symptoms than in studies with contemporaneous enrolment. To further illustrate the heterogeneity in exposure assessment between and within the studies, we provide additional aggregations of the data in Extended data, Supplementary File 3.

Population level. At a population level, Mier-Y-Teran-Romero et al. (2018) found that the estimated incidence of GBS ranged between 1.4 (0.4–2.5) and 2.2 (0.8–5.0) per 10,000 ZIKV infections comparing surveillance/reported cases from Brazil, Colombia, Dominican Republic, El Salvador, French, Honduras, Puerto Rico, Suriname, Venezuela, and Micronesia. The cross-location minimum and maximum estimates were used to estimate an average risk of having GBS and being reported after ZIKV infection across locations of approximately 2.0 GBS cases per 10,000 infections (95% credible interval 0.5–4.5 per 10,000 ZIKV infections).

Dose response. In a case-control study, Lynch et al. (2018) found higher titres of neutralising antibodies in ZIKV-infected...
GBS cases than in patients with symptomatic ZIKV infection but without GBS.

**Specificity.** Dirlikov et al. (2018) compared Puerto Rican GBS cases reported through public health surveillance that were preceded by ZIKV and cases that were not preceded by ZIKV infection. Clinical features involving cranial nerves were observed more frequently in ZIKV-related cases and, at a six-month follow-up visit, residual cranial neuropathy was noted more often in this group. However, clinical symptoms did not allow a distinction to be made between ZIKV and non-ZIKV related GBS.

**Consistency. Geographical region:** During this review period, GBS likely due to ZIKV infection was reported in Asia; including Thailand, Bangladesh, Singapore and India. Publication in the WHO Region of the Americas followed the pattern as observed before and no GBS linked to ZIKV infection was reported in Africa. Extended data, Supplementary File 3 provides a full overview of the included studies.

**Traveller/non-traveller populations:** In studies included in this update, we found additional evidence of GBS in both travellers and non-travellers with ZIKV infection. Ten publications report on 11 travellers, while 34 publications report GBS due to ZIKV in 402 non-travellers.

**Study designs:** Across the different study designs, the relation between GBS and ZIKV is consistently shown. Table 2 and Extended data, Supplementary File 3 provide an overview of the included study designs.

**Lineages:** We still lack evidence on the consistency of the relation between GBS and ZIKV across different lineages from observational studies. The observed cases of GBS were linked to ZIKV of the Asian lineage.

**Risk of bias assessment**
Potential selection bias in case-control studies was introduced by the selection of controls: Hospital controls, or community/household controls. Most similar exposure assessment measures are compared (IgM, recent flavivirus infection, or IgM and/or RT-PCR). OR: 7.0 [95% CI: 1.7-28.8, tau2=2.78, I²=78.3%]. ORs from studies marked with an asterisk (*) are matched ORs, unmarked studies provided crude ORs. The latest and previous versions of this figure are available as extended data.

### Figure 6. Forest plot of six included case-control studies and their exposure assessment.
Odds ratios (ORs) are shown on the log-scale. The meta-analysis is stratified by the selection of controls: Hospital controls, or community/household controls. Most similar exposure assessment measures are compared (IgM, recent flavivirus infection, or IgM and/or RT-PCR). OR: 7.0 [95% CI: 1.7-28.8, tau2=2.78, I²=78.3%]. ORs from studies marked with an asterisk (*) are matched ORs, unmarked studies provided crude ORs. The latest and previous versions of this figure are available as extended data.
of the causal relationship between ZIKV infection and adverse congenital outcomes and GBS, published between January 18, 2017 and July 1, 2019.

Strengths and limitations

The strengths of this living systematic review are, first, that we automated much of the workflow; we searched both international and regional databases daily and we screen papers for eligibility as they became available, so publication bias is unlikely. Second, we have quantified the strength of association between ZIKV infection and congenital abnormalities and GBS and investigated heterogeneity of outcome and exposure assessment within and between studies. Third, for congenital outcomes, we included studies with both microcephaly and other possible adverse outcomes, acknowledging the spectrum of congenital adverse outcomes caused by ZIKV. This work also has several limitations. First, we have not assessed the dimensions of the causality framework that involve laboratory studies, so we have not updated the pathobiology of ZIKV complications, which was addressed in the baseline review and the first update to January 2017. Limiting the review to epidemiological domains has allowed more detailed analyses of these studies and we hope that laboratory scientists will continue to review advances in these domains. Second, the rate of publications on ZIKV remains high so, despite the reduced scope and automation, maintenance of the review is time-consuming and data extraction cannot be automated. Third, this review may suffer from continuity bias, which is important for the conduct and interpretation of living systematic reviews and results from changes in the author team. Careful adherence to the protocol will reduce this risk.

Interpretation of the findings

ZIKV and congenital abnormalities: Since the earlier versions of the review, evidence on the causal relationship between ZIKV infection and congenital abnormalities has expanded. Unfortunately, the total number of cases investigated in the published cohort or case-control studies remains small. In case-control studies in which infants with microcephaly or other congenital abnormalities are compared with unaffected infants, the strength of association differs according to whether exposure to ZIKV is assessed in the mother (OR 3.8, 95% CI: 1.7-8.7, tau²=0.18, I²=19.8%) or the foetus/infant (OR 37.4, 95% CI: 11.0-127.1, tau²=0, I²=0%). This large difference in effect size can be attributed to the fact that not all maternal ZIKV infections result in foetal infection. In cohort studies, the risk of congenital abnormalities was 3.5 times higher (95% CI: 0.9-13.5, I²=0%, tau²=0) in mothers with evidence of ZIKV infection than without, which is similar to the OR for maternal exposure to ZIKV estimated from case-control studies. Further research is needed to understand the drivers of mother to child transmission. Higher maternal antibody titres were correlated with a higher incidence of adverse congenital outcomes in one case-control study. However, amongst ZIKV-infected mothers followed prospectively, severity of ZIKV infection was not associated with more severe congenital abnormalities. Convincing evidence on a dose-response relation is therefore still lacking.

ZIKV and GBS: Evidence on the causal relation between ZIKV infection and GBS has grown since our last review. The body of evidence is still smaller than that for congenital abnormalities, possibly because GBS is a rare complication, estimated to occur in 0.24 per 1000 ZIKV infections. In this review, the strength of association between GBS and ZIKV infection, estimated in case-control studies, tended to be lower than observed in the first case-control study reported by Cao-Lormeau (2016) in French Polynesia. It is possible that the finding by Cao-Lormeau et al. was a ‘random high’, a chance finding. Simon et al., however, found a similarly strong association in a case-control study in New Caledonia. In both these studies, controls were patients in the same hospital. Although matched for place of residence, it is possible that they were less likely to have been exposed to ZIKV than the cases, resulting in an overestimation of the OR. In case-control studies in which controls were enrolled from the same communities as the cases, estimated ORs were lower, presumably because exposure to ZIKV amongst community-enrolled controls is less biased than amongst hospital controls.

Under-ascertainment of ZIKV infection in case-control studies in which enrolment occurred several months after the onset of symptoms is also likely to have reduced the observed strength of association. There is also possible evidence of a dose-response relationship, with higher levels of neutralising antibodies to both ZIKV and dengue in people with GBS. However, the level of antibody titre might not be an appropriate measure of viral titre, and merely a reflection of the intensity of the immune response. Taking into account the entire body of evidence, inference to the best explanation supports the conclusion that ZIKV is a cause of GBS. The prospect of more precise and robust estimates of the strength of association between ZIKV and GBS is low because outbreaks need to be sufficiently large to enrol enough people with GBS. In the large populations that were exposed during the 2015–2017 outbreak, herd immunity will limit future ZIKV outbreaks.

Implications for future research

The sample sizes of studies published to date are smaller than those recommended by WHO for obtaining precise estimates of associations between ZIKV and adverse outcomes [Harmonization of ZIKV Research Protocols to Address Key Public Health]. Given the absence of large new outbreaks of ZIKV infection in 2017–2019, there is a need for consortia of researchers to analyse their data in meta-analyses based on individual participant data [Individual Participant Data Meta-analysis of Zika-virus related cohorts of pregnant women (ZIKV IPD-MA)]. Future collaborative efforts will help to quantify the absolute risks of different adverse congenital outcomes and allow investigation of heterogeneity between studies.

This review highlights additional research gaps. We did not assess the complication rates within the infected group in studies without an unexposed comparison group; the adverse outcomes are not pathognomonic for ZIKV infection, making an appropriate comparison group necessary. Although there are no individual features of ZIKV infection that are completely specific, the growing number of publications on ZIKV will
allow better ascertainment of the features of a congenital Zika syndrome\textsuperscript{35}. In this review, we did not take into account the performance of the diagnostic tests in assessing the strength of association. Future research should include robust validation studies, and improved understanding of contextual factors in the performance of diagnostic tests, including the influence of previous circulation of other flaviviruses, the prevalence of ZIKV and the tests used.

This living systematic review will continue to follow studies of adverse outcomes originating from ZIKV circulation in the Americas, but research in regions with endemic circulation of ZIKV is expected to increase. Such studies will clarify whether ZIKV circulation in Africa and Asia also results in adverse outcomes, as suggested by the case-control study of GBS from Bangladesh\textsuperscript{36}. Increased awareness might improve the evidence-base in these regions, where misperceptions about the potential risks of ZIKV-associated disease with different virus lineages has been reported\textsuperscript{37}. An important outstanding question remains whether the absence of reported cases of congenital abnormalities or GBS in these regions represent a true absence of complications or is this due to weaker surveillance systems or reporting\textsuperscript{38}. The conclusions that ZIKV infection causes adverse congenital outcomes and GBS are reinforced with the evidence published between January 18, 2017 and July 1, 2019.

Data availability

Underlying data
All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Harvard dataverse: Living systematic review on adverse outcomes of Zika - Supplementary Material. https://doi.org/10.7910/DVN/S7USU1\textsuperscript{17}

This project contains the following extended data:

- SupplementaryFile1Prisma.docx (PRISMA checklist)
- SupplementaryFile2Methods.docx (Supplementary file 2, additional information to the Methods)
- SupplementaryFile3Results.docx (Supplementary file 3, additional information to the Results)
- SupplementaryFile4ROB.tab (Risk of bias assessment)

Harvard dataverse: Living systematic review on adverse outcomes of Zika - Figures and Table. https://doi.org/10.7910/DVN/DLP5AN\textsuperscript{16}

This project contains the following extended data:

- Fig1.pdf (Most recent version of Figure 1)
- Fig2.pdf (Most recent version of Figure 3, PRISMA flowchart)
- Fig3A.pdf (Most recent version of Figure 4A)
- Fig3B.pdf (Most recent version of Figure 4B)
- Fig4.pdf (Most recent version of Figure 5)
- Fig5.pdf (Most recent version of Figure 6)
- Table1.pdf (Most recent version of Table 1)
- Table2.pdf (Most recent version of Table 2)

Reporting guidelines

PRISMA checklist and flow diagram for ‘Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: A living systematic review’, https://doi.org/10.7910/DVN/S7USUI and Figure 2.

Grant information

This work was supported by the Swiss National Science Foundation [320030_170069], end date: 31/10/2021.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclaimer

The views expressed in this article are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention.

References

II. Post-Mortem Analyses of Neonates with Microcephaly, Stillbirths, and S401–S.


Reference Source


Reference Source


Reference Source


The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com